AMLN Amylin Pharmaceuticals, Inc. (MM)

SAN DIEGO, Sept. 28 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc. (NASDAQ:AMLN) today announced that Karin Eastham has been elected to the company's board of directors effective immediately. Ms. Eastham will serve on Amylin's audit committee. "We are very excited to welcome Karin to the Amylin team," said Ginger L. Graham, President and CEO of Amylin Pharmaceuticals. "Her extensive financial and operations management experience in the life sciences industry will be a great asset to our Board." Ms. Eastham has over 25 years experience in financial and operations management, primarily in life sciences companies. She currently serves as Executive Vice President and Chief Operating Officer, and as a member of the Board of Trustees of the Burnham Institute for Medical Research, a non-profit corporation, engaged in basic biomedical research and the home to three research centers -- a Cancer Center, the Del E. Webb Center for Neuroscience and Aging and a Center for research on Infectious and Inflammatory Diseases. From April 1999 to May 2004, Ms. Eastham served as Senior Vice President, Finance, Chief Financial Officer, and Secretary of Diversa Corporation, where she led the company's IPO, raising over $200 MM. She previously held similar positions with CombiChem, Inc., a computational chemistry company, and Cytel Corporation, a biopharmaceutical company. Ms. Eastham also held several positions, including Vice President, Finance, at Boehringer Mannheim Corporation, from 1976 to 1988. Ms. Eastham also serves as a director for Tercica, Inc. and Illumina, Inc, public biotechnology companies, and SGX Pharmaceuticals, Inc. and Cyntellect, Inc. private biotechnology companies. She also serves on the Board of UCSD's Athena Program. Ms. Eastham received a B.S. and an M.B.A. from Indiana University and is a Certified Public Accountant and a Certified Director. Amylin Pharmaceuticals is a biopharmaceutical company committed to improving lives through the discovery, development and commercialization of innovative medicines. DATASOURCE: Amylin Pharmaceuticals, Inc. CONTACT: Alice Bahner, Executive Director, Investor Relations of Amylin Pharmaceuticals, Inc., +1-858-552-2200, ext. 7272 Web site: http://www.amylin.com/

Copyright